Biotech IPO window is opening but big pharma M&A still leaders, top bankers say
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Biotech IPO window is opening but big pharma M&A still leaders, top bankers say basliginda one cikan gelisme: Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.